Status:
COMPLETED
Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Collaborating Sponsors:
Innate Pharma
Conditions:
COVID
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical...
Eligibility Criteria
Inclusion
- COVID-19 severe pneumonia patients need for oxygen therapy ≥ 5 l/min or high-flow oxygen therapy
- COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation
Exclusion
- Pregnant woman
- Uncontrolled sepsis of bacterial or fungal origin
Key Trial Info
Start Date :
April 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT04371367
Start Date
April 27 2020
End Date
March 30 2021
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Marseille
Marseille, France, 13354